Our latest study finds that telling people alcohol causes cancer makes them want to drink less. Encouraging them to count their drinks helps them do it.
Mitigating COVID-19 risk in Urban Slums - Lessons for future
As the COVID-19 pandemic ravages through the country it brings out the vulnerabilities in health system. If first wave was confined to urban districts, in the past few months, the cases have grown at an alarming rate and the locus has moved to rural areas where health care access is scarce, and infrastructure is fragile.
The past year offers some lessons on factors (facilitators and barriers) that impede the onslaught of COVID-19 pandemic and these learnings will help in better planning of mitigation strategies for future.
Goal for the webinar:
Share learnings of community-based interventions to mitigate COVID-19 risk and effects in low resource urban slum settings
Prepare and support other implementers and policy makers to develop interventions and policies to flatten COVID-19 curve in future.
Theme
Webinar is based on the theme of ‘Supporting communities to mitigate COVID-19 risk’. Partners working in the urban slums of Mumbai and Chennai will share their experiences on working with communities during 1st wave of COVID-19 and the strategies that were used to mitigate COVID-19 in the intervention sites.
Mark your calendars for 22nd June 2021 | Tuesday | 6:00 - 7:30 PM IST
Use of convalescent plasma in patients hospitalised with COVID-19
The International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) in association with other partners including the George Institute for Global Health, India is organising a webinar on “Use of convalescent plasma in patients hospitalised with COVID-19”
10th June 2021
British Summer Time (BST), 9:00 am
Central European Summer Time (CEST), 10:00 am
Central Africa Time (CAT), 10:00 am
Moscow Standard Time (MSK), 11:00 am
Indian Standard Time (IST), 13:30 pm
China Standard Time (CST), 14:00 pm
Australia Eastern Standard Time (AEST), 18 pm
ISARIC partners have been at the forefront of clinical trials of COVID-19 treatments since the start of the pandemic. Recognising how hard it is to keep up with the extraordinary pace of COVID science, ISARIC was running a series of ‘Evidence Fora’ on COVID-19 treatment.
Plasma from patients who have recovered from SARS-CoV-2 infection (convalescent plasma) contains antibodies that can bind to and neutralise the virus. Infusion of convalescent plasma containing high concentrations of neutralising antibody may theoretically accelerate clearance of the virus and clinical improvement. Although convalescent plasma has been widely used in patients admitted to hospital with COVID-19, data from randomised controlled trials in this patient group have, until recently, been limited.
This webinar provides evidence from randomised controlled trials of the safety and efficacy of convalescent plasma in patients hospitalised for COVID-19.
Speakers
Soumyadeep Bhaumik International Public Health Specialist, George Institute for Global Health
Peter Horby Executive Director, ISARIC
Aparna Mukherjee Senior Scientist, Indian Council of Medical Research
Moderator
Bharath Kumar Consultant in Critical Care, Department of Critical Care, Apollo Hospitals
Objectives of this forum
To provide up-to-date information from randomised controlled trials on evidence of the effectiveness and safety of convalescent plasma in patients admitted to hospital with COVID-19.
To identify key questions for translating the clinical trial evidence on the use of convalescent plasma in patients admitted to hospital with COVID-19 into clinical practice.
